Therapeutic Solutions International, Inc. (TSOI)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -1.48 Million USD | 43.15% |
| 2022 | -2.98 Million USD | -28.85% |
| 2021 | -2.33 Million USD | -23.63% |
| 2020 | -1.89 Million USD | -78.41% |
| 2019 | -1.33 Million USD | 13.6% |
| 2018 | -1.19 Million USD | -35.68% |
| 2017 | -884.26 Thousand USD | 15.15% |
| 2016 | -1.04 Million USD | -82.54% |
| 2015 | -545.93 Thousand USD | -92.08% |
| 2014 | -305.97 Thousand USD | 44.63% |
| 2013 | -825.04 Thousand USD | 48.36% |
| 2012 | -1.82 Million USD | -17.32% |
| 2011 | -743.15 Thousand USD | -91.26% |
| 2010 | -458.22 Thousand USD | 69.88% |
| 2009 | -1.53 Million USD | -1579.66% |
| 2008 | -91.54 Thousand USD | -430.37% |
| 2007 | -17.26 Thousand USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -673.24 Million USD | -98.01% |
| 2024 Q2 | -327.13 Thousand USD | 47.74% |
| 2023 Q1 | -352.95 Thousand USD | 56.92% |
| 2023 FY | - USD | 43.15% |
| 2023 Q4 | -475.73 Thousand USD | 99.9% |
| 2023 Q3 | -457.33 Million USD | -98126.56% |
| 2023 Q2 | -465.59 Thousand USD | -31.91% |
| 2022 Q1 | -586.37 Thousand USD | 35.49% |
| 2022 Q4 | -819.32 Thousand USD | -29.71% |
| 2022 Q2 | -975.1 Thousand USD | -66.29% |
| 2022 Q3 | -631.66 Thousand USD | 35.22% |
| 2022 FY | - USD | -28.85% |
| 2021 Q4 | -908.91 Thousand USD | -30.29% |
| 2021 Q1 | -259.08 Thousand USD | 52.75% |
| 2021 Q2 | -420.64 Thousand USD | -62.36% |
| 2021 Q3 | -697.63 Thousand USD | -65.85% |
| 2021 FY | - USD | -23.63% |
| 2020 FY | - USD | -78.41% |
| 2020 Q1 | -120.72 Thousand USD | 44.29% |
| 2020 Q2 | -691.63 Thousand USD | -472.89% |
| 2020 Q3 | -488.63 Thousand USD | 29.35% |
| 2020 Q4 | -548.27 Thousand USD | -12.21% |
| 2019 Q3 | -199.62 Thousand USD | -2.78% |
| 2019 Q2 | -194.23 Thousand USD | 55.1% |
| 2019 Q1 | -432.59 Thousand USD | 15.19% |
| 2019 Q4 | -216.71 Thousand USD | -8.56% |
| 2019 FY | - USD | 13.6% |
| 2018 Q3 | -256.59 Thousand USD | -9.52% |
| 2018 FY | - USD | -35.68% |
| 2018 Q1 | -198.82 Thousand USD | 22.65% |
| 2018 Q2 | -234.29 Thousand USD | -17.84% |
| 2018 Q4 | -510.09 Thousand USD | -98.79% |
| 2017 FY | - USD | 15.15% |
| 2017 Q4 | -257.05 Thousand USD | -23.75% |
| 2017 Q3 | -207.71 Thousand USD | 13.35% |
| 2017 Q2 | -239.73 Thousand USD | -33.36% |
| 2017 Q1 | -179.76 Thousand USD | 50.15% |
| 2016 Q4 | -360.58 Thousand USD | -101.02% |
| 2016 Q1 | -225.65 Thousand USD | -10.35% |
| 2016 Q3 | -179.38 Thousand USD | 35.14% |
| 2016 FY | - USD | -82.54% |
| 2016 Q2 | -276.54 Thousand USD | -22.55% |
| 2015 Q3 | -178.49 Thousand USD | -55.56% |
| 2015 Q4 | -204.49 Thousand USD | -14.57% |
| 2015 FY | - USD | -92.08% |
| 2015 Q1 | -74.87 Thousand USD | -6514.66% |
| 2015 Q2 | -114.74 Thousand USD | -53.24% |
| 2014 FY | - USD | 44.63% |
| 2014 Q1 | -44.1 Thousand USD | -89.83% |
| 2014 Q4 | -1132.00 USD | 98.08% |
| 2014 Q3 | -58.9 Thousand USD | 51.79% |
| 2014 Q2 | -122.18 Thousand USD | -177.04% |
| 2013 Q2 | -218.51 Thousand USD | -34.21% |
| 2013 FY | - USD | 48.36% |
| 2013 Q4 | -23.23 Thousand USD | 79.21% |
| 2013 Q1 | -162.81 Thousand USD | -296.26% |
| 2013 Q3 | -111.76 Thousand USD | 48.86% |
| 2012 Q1 | -325.04 Thousand USD | 33.09% |
| 2012 Q4 | 82.96 Thousand USD | 116.54% |
| 2012 Q3 | -501.5 Thousand USD | -69.51% |
| 2012 FY | - USD | -17.32% |
| 2012 Q2 | -295.85 Thousand USD | 8.98% |
| 2011 Q3 | -346.93 Thousand USD | -698.15% |
| 2011 Q4 | -485.75 Thousand USD | -40.01% |
| 2011 FY | - USD | -91.26% |
| 2011 Q1 | -9806.00 USD | -219.93% |
| 2011 Q2 | -43.46 Thousand USD | -343.27% |
| 2010 Q2 | -96.77 Thousand USD | 64.98% |
| 2010 Q4 | -3065.00 USD | 96.48% |
| 2010 Q3 | -87.02 Thousand USD | 10.07% |
| 2010 Q1 | -276.35 Thousand USD | 36.92% |
| 2010 FY | - USD | 69.88% |
| 2009 Q2 | -433.42 Thousand USD | -55.59% |
| 2009 FY | - USD | -1579.66% |
| 2009 Q3 | -393.28 Thousand USD | 9.26% |
| 2009 Q4 | -438.12 Thousand USD | -11.4% |
| 2009 Q1 | -278.57 Thousand USD | -61259.25% |
| 2008 Q2 | -44.94 Thousand USD | 18.24% |
| 2008 FY | - USD | -430.37% |
| 2008 Q3 | -5000.00 USD | 88.88% |
| 2008 Q4 | -454.00 USD | 90.92% |
| 2008 Q1 | -54.97 Thousand USD | -466.12% |
| 2007 Q3 | -7550.00 USD | 0.0% |
| 2007 FY | - USD | 0.0% |
| 2007 Q4 | -9711.00 USD | -28.62% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 97.906% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | 74.913% |
| SQZ Biotechnologies Company | -64.14 Million USD | 97.681% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 91.437% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 101.582% |
| Mesoblast Limited | -62.38 Million USD | 97.616% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 3.166% |
| Genus plc | 73.7 Million USD | 102.018% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | 77.503% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | 58.066% |
| Marizyme, Inc. | -34.28 Million USD | 95.661% |
| ContraFect Corporation | -64.99 Million USD | 97.712% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 83.044% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | 67.138% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -6.107% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | 43.753% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | 35.993% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -187.12% |
| Accustem Sciences Inc. | -3.74 Million USD | 60.298% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 96.916% |
| EV Biologics, Inc. | -1.26 Million USD | -17.384% |
| Q BioMed Inc. | -617.62 Thousand USD | -140.827% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 141.641% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -135.199% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | 34.891% |
| Biomind Labs Inc. | -1.03 Million USD | -43.774% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 9.87 Million USD | 115.059% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | 79.23% |
| Skye Bioscience, Inc. | -13.54 Million USD | 89.021% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -5849.648% |
| Arch Therapeutics, Inc. | -3.88 Million USD | 61.707% |
| IMV Inc. | -35.52 Million USD | 95.813% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 90.627% |
| Curative Biotechnology, Inc. | -2.5 Million USD | 40.55% |
| GB Sciences, Inc. | -1.41 Million USD | -4.756% |
| Alpha Cognition Inc. | -9.7 Million USD | 84.675% |
| HST Global, Inc. | -5303.00 USD | -27948.501% |
| CSL Limited | 4.78 Billion USD | 100.031% |
| Halberd Corporation | -74.27 Thousand USD | -1902.466% |
| Enzolytics Inc. | -2.12 Million USD | 29.906% |
| Resverlogix Corp. | -11.74 Million USD | 87.333% |
| Affymax, Inc. | -14.29 Million USD | 89.595% |
| SYBLEU INC | -141.57 Thousand USD | -950.647% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | 51.44% |
| argenx SE | -216.02 Million USD | 99.311% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 97.312% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 222.22% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | 0.767% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 492.619% |
| AVAX Technologies, Inc. | -6.11 Million USD | 75.667% |
| Zenith Capital Corp. | -8.6 Million USD | 82.717% |
| Genscript Biotech Corporation | -248.71 Million USD | 99.402% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -8438.04% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | 39.201% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -745.003% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 96.247% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | 48.574% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -1.04 Million USD | -42.158% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 22220.94% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.74 Million USD | 15.005% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | 22.567% |
| BioStem Technologies, Inc. | -7.55 Million USD | 80.309% |
| ONE Bio Corp. | 13.61 Million USD | 110.926% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -721.375% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Wesana Health Holdings Inc. | -2.05 Million USD | 27.69% |
| Agentix Corp. | -1.37 Million USD | -8.431% |
| LadRx Corporation | 412.28 Thousand USD | 460.775% |
| Cell Source, Inc. | -4.27 Million USD | 65.187% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -305.045% |
| Regen BioPharma, Inc. | 1.46 Million USD | 201.464% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | -58.751% |
| NovAccess Global Inc. | -1.03 Million USD | -43.739% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 116.8% |
| Itoco Inc. | -1.86 Million USD | 20.416% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -291.816% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -33.281% |
| Kadimastem Ltd | -2.62 Million USD | 43.323% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -521.958% |
| CytoDyn Inc. | -18.02 Million USD | 91.75% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -1782.109% |
| Mobile Lads Corp. | -2.24 Million USD | 33.632% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -12062.99% |
| Qrons Inc. | -40.08 Thousand USD | -3611.015% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -206.255% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 382.01% |
| Rebus Holdings, Inc. | -951 Thousand USD | -56.405% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | -40.056% |
| International Stem Cell Corporation | 202 Thousand USD | 836.343% |
| Bioxytran, Inc. | -3.82 Million USD | 61.064% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -2725.631% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | 39.584% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 95.853% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -3205.36% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | 45.675% |
| Neutra Corp. | -181.24 Thousand USD | -720.655% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 92.622% |
| PureTech Health plc | -11.62 Million USD | 87.207% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 92.621% |
| IXICO plc | -707 Thousand USD | -110.384% |
| IntelGenx Technologies Corp. | -7.68 Million USD | 80.645% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 96.923% |
| CSL Limited | 4.73 Billion USD | 100.031% |
| Cellectis S.A. | -92.63 Million USD | 98.394% |